Manila FY2026 First Three Quarters: Dental Sales in China Approximately 128 Million RMB, Up 49% Year-on-Year

Source: Mani FY2026 First Three Quarters Consolidated Financial Results

Net sales in the first three quarters up 9.5% year-on-year / Dental segment operating profit up 102.4% year-on-year / Full-year net profit attributable to shareholders of the parent company forecast

DentalGoodNews｜Japanese oral consumables company MANI, Inc. recently released its consolidated financial results for the nine months ended May 31, 2026 (FY2026 first three quarters). During the reporting period, the company's net sales were 24.396 billion yen (approximately 1.095 billion yuan, converted at the average exchange rate of 1 CNY = 22.28 JPY for the third quarter of FY2026), up 9.5% year-on-year; net profit attributable to shareholders of the parent company was 5.642 billion yen (approximately 253 million yuan), up 32.6% year-on-year. Based on the performance in the first three quarters, the company simultaneously raised its full-year earnings forecast, adjusting the net profit attributable to shareholders of the parent company target from the previous 6.450 billion yen (approximately 290 million yuan) to 6.8 billion yen (approximately 305 million yuan).

In the first three quarters, the company's operating profit was 7.486 billion yen (approximately 336 million yuan), up 22.0% year-on-year; ordinary profit was 8.036 billion yen (approximately 361 million yuan), up 33.3% year-on-year. The growth rate of ordinary profit exceeded that of operating profit, mainly due to the impact of foreign exchange gains. The company disclosed that foreign exchange gains during the reporting period were 659 million yen (approximately 29.6 million yuan).

Source: Mani FY2026 First Three Quarters Consolidated Financial Results

According to the company's disclosure, the profit growth in the first three quarters mainly came from the recovery of the dental segment. The dental segment recorded sales of 8.103 billion yen (approximately 364 million yuan), up 16.2% year-on-year; operating profit was 1.473 billion yen (approximately 66.1 million yuan), up 102.4% year-on-year, the highest growth rate among all business segments. In terms of the overall absolute value of the China dental business, cumulative dental sales in China for FY2026 first three quarters reached 2.844 billion yen (approximately 128 million yuan), an increase of about 49% compared to the same period in FY2025, accounting for 35% of the total dental segment sales in the first three quarters.

The company stated that the recovery of the China dental business was mainly driven by the sales recovery of DIA-BURS (diamond grinding tools). Due to issues related to product registration with Chinese regulatory authorities, MANI initiated a voluntary recall of some DIA-BURS products in March 2025, which was largely completed by August of the same year. The recalled products received regulatory approval in October and resumed sales in November. The company disclosed that the sales recovery of DIA-BURS exceeded the original plan, which aimed to restore sales to about 90% of pre-recall levels within two years. Specifically, DIA-BURS sales in FY2026 Q1 recovered to 37% of the same period in FY2024, Q2 recovered to 156%, and Q3 recovered to 87%.

Source: Mani FY2026 First Three Quarters Consolidated Financial Results

In addition, the company raised its full-year FY2026 earnings forecast: annual net sales were raised from 32.8 billion yen (approximately 1.472 billion yuan) to 32.9 billion yen (approximately 1.477 billion yuan); operating profit was raised from 9.2 billion yen (approximately 413 million yuan) to 9.7 billion yen (approximately 435 million yuan); net profit attributable to shareholders of the parent company was raised from 6.450 billion yen (approximately 290 million yuan) to 6.8 billion yen (approximately 305 million yuan), corresponding to earnings per share (EPS) of 69.03 yen. Based on the actual net profit attributable to shareholders of the parent company of 4.643 billion yen (approximately 208 million yuan) in FY2025, the revised full-year forecast represents an increase of 46.4% year-on-year.